Abstract

26
Our current therapeutic drugs for Alzheimer's disease (AD) are predominantly derived from 27 the alkaloid class of plant phytochemicals. These drugs, such as Galantamine and
28
Rivastigmine, attenuate the decline in the cholinergic system but, as the alkaloids occupy the 29 most dangerous end of the phytochemical spectrum (indeed they function as feeding 30 deterrents and poisons to other organisms within the plant itself), they are often associated 31 with unpleasant side effects. In addition, these cholinesterase inhibiting alkaloids target only 32 1 system in a disorder which is typified by multifactorial deficits. The more benign terpene underlying this body of research is that the supplementation of these compounds will, via a 55 multitude of mechanisms, enhance some aspect/s of cognitive function, mood and/or physical 56 performance. Naturally these studies produce varied results with some robust results evinced 57 from compounds such as caffeine (1) , the neural substrates oxygen (2; 3) and glucose (4) and, more 58 recently, supplementation of the water soluble vitamins (5) . However, other supplemented 59 compounds appear almost to elicit no cognitive benefit to the young, healthy cohorts utilized; 60 the polyphenol resveratrol, for example (6; 7; 8) . This has led to the conclusion that some 61 supplements may have limited cognitive benefit in those who are within the cognitive peak 62 age-range (i.e. 18-35yrs) (9) and that the mechanism underpinning their purported activity , glucose regulation (18) , cerebral blood flow (19) , inflammation (20) , ferrous metals , socioeconomic status (23) and many more known and unknown variables.
83
The morphological changes to neurons that the above risk factors mediate are seen to 84 predominantly disrupt the cholinergic neurotransmitter system and, in turn, the cognitive 85 processes that the ubiquitous neurotransmitter acetylcholine sub-serves. Hence the 86 progressive, global deficits in cognitive function seen in AD and the rationale for the target of 87 current pharmaceutical drugs in attenuating this cholinergic decline (24) . These drugs include
88
Galantamine and Rivastigmine and, as a group of drugs defined as cholinesterase inhibitors
89
(preventing the deamination of acetylcholine), these are currently the only approved first line 90 pharmacologic treatment for AD in the UK (25) . A recent Cochrane review reported that these 91 drugs attenuate the decline in cognition, daily living and behaviour in AD when compared to 92 placebo (26) but, interestingly, highlighted that none of the treatment effects were large.
93
Cholinesterase drugs also lack efficacy in some stages of AD and here use of the 94 antipsychotic drug Risperidone is often turned to in order the mediate challenging 95 behaviour (27) . Cholinesterase drugs are also associated with some quite unpleasant side effects
96
(including gastrointestinal problems (26) ) and this is likely related to their current derivation 97 from the alkaloid spectrum of plant secondary metabolites (hereafter referred to as 98 phytochemicals). and their role appears to be one of protection; expressed as they are when the plant comes 108 under some kind of stress (28) . Of interest here, many phenolic and terpene phytochemicals . the AD groups (36) . In the same year a review of 6 studies found that 6 months administration 148 of ginkgo resulted in significant improvements on the ADAS-cog (37) . enhance CNS function and prevent cardiovascular and other diseases in animal models (42) .
167
Specific neurocognitive interactions with neurotransmitter function and the processes of 168 neurogenesis and long-term potentiation are also observed to exert anti-stress, antidepressant,
169
and anxiolytic effects, to moderate fatigue and improve memory in impaired rodents (43; 44) .
170
Research in young healthy participants is still in its infancy and buoyed by heterogeneous 
. In vitro and animal data supports the potential for ginseng to be of specific benefit to AD-173 induced cognitive decline where ginsenosides have been observed to minimise the inhibitory effect of amyloid-β protein on cholinergic transmission (49) and, in turn, prevent the resulting 175 amnesiac effects in rats (50) . To the best of current knowledge, however, only 2 trials exist 176 which investigate whether these cognitive benefits also extend to AD in humans. Melissa tincture in a group of mild-moderate sufferers (61) . The other of the 2 studies,
195
however, failed to find statistically significant differences in AD symptoms with Melissa (62) . . These CNS effects produce enhanced secondary memory, accuracy and attention 
. The latter study didn't observe any statistically significant cognitive benefit but this was not the a priori aim of the study and this is reflected in the sample size.
225
Nevertheless the authors do report 'positive indications' on the cognitive test battery used
226
(CDR) and this is in line with the only other trial investigating the benefit of sage in AD (69) .
227
Here 19 participants (65-80yrs), with mild-moderate AD, consumed an SO-alcoholic tincture 228 for 16 weeks and better outcomes on the ADAS-cog, compared to the placebo controls, was
229
observed. This study also demonstrated a trend towards reduced agitation in the SO group. (which can be further sub-categorised into flavan-3-ols (found in tea) and proanthocyanidins
237
(found in fruits)), flavonols (fruits and vegetables; specifically onions) and anthocyanins
238
(specifically found in berries) (70) .
239
Epidemiological data has established links between the consumption of polyphenol-rich diets, .
256
Interaction with these targets, and others like upregulation of CBF (6; 7) , and the ability of 257 resveratrol to attenuate amyloid-β induced cell death in vitro (81) , suggests that this polyphenol
258
should be capable of beneficial therapeutic potential in AD. Indeed, results from animal 259 models supports the function of resveratrol here with reduced markers of pathology, e.g.
260
amyloid-β plaques (82) , and behavioural deficits, e.g. improved learning and memory (83) , in 261 response to resveratrol exposure and consumption (25mg/kg/day) of resveratrol respectively.
262
However, to the best of current knowledge, only 1 study exists which investigates resveratrol 263 in human volunteers with AD. Here a phase-2 randomized, placebo-controlled, double-blind 264 12 month trial of 500mg/day (escalating to 1000mg x2 daily) resveratrol was conducted in 265 participants with mild-moderate AD (84) . Unfortunately the therapeutic measures of this study 266 were limited and, whilst amyloid-β markers were reduced by resveratrol, this was not more 267 significant than in the placebo group, and brain volume loss was not attenuated. Resveratrol of efflux pumps and these factors will be unique to each participant. It's likely that the impact 291 of these individual differences will be diluted in large cohorts but, apart from the meta- 
